SEC Form 4 · accession 0001140361-16-085872
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan W Ayers
Officer — Chairman, President & CEO · Director
Period of report
Nov 9, 2016
Accepted (ET)
Nov 10, 2016 · 5:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 9, 2016 | M | 40,000 | $26.655 | A | 1,027,855 | D | |
| Common StockF2,F3 | Nov 9, 2016 | S | 5,767 | $106.2535 | D | 1,022,088 | D | |
| Common StockF2,F4 | Nov 9, 2016 | S | 6,433 | $107.4776 | D | 1,015,655 | D | |
| Common StockF2,F5 | Nov 9, 2016 | S | 27,800 | $108.2741 | D | 987,855 | D | |
| Common Stock | holding | — | — | — | 98,000 | I | by Ayers Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right-to-buy)F7,F6 | $26.655 | Nov 9, 2016 | M | 40,000 | D | — | Feb 13, 2017 | Common Stock | 40,000 | 36,250 | D |
Explanation of responses
- F1Includes 65 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2016.
- F2Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F3Represents the weighted average sales price of the shares sold ranging from a low of $105.81 to a high of $106.81 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4Represents the weighted average sales price of the shares sold ranging from a low of $106.87 to a high of $107.835 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5Represents the weighted average sales price of the shares sold ranging from a low of $107.90 to a high of $108.81 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F6Grant of option to buy 78,125 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 16,000 shares each beginning on February 14, 2011 and as to the remaining 14,125 shares on February 14, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F7Not applicable.